by Rod Raynovich | Dec 1, 2009 | BIOgraph
Global market growth for vaccines forecasted at 12% ( Edited version published in Genetic Engineering News Dec. 1, 2009) The potential H1N1pandemic has drawn renewed interest in vaccines. Vaccines over the last 100+ years have been one of the most important agents for...
by Rod Raynovich | Nov 18, 2009 | BIOgraph
After a nasty October correction of 10%, biotech stocks are in a recovery mode and poised for a Q4 rally extending to early January. This trend was intact in the past (check ’05,’06, and ’07 trends) but was disrupted by the recent financial crisis of ‘08/09. A nice...
by Rod Raynovich | Nov 16, 2009 | BIOgraph
Biotech stocks continue to rally off the early November bottom despite bad news from Poniard (PARD) because of the picoplatin study failure. PARD was down 76% at 12:09p. The recent news of Sanofi-Aventis adding $800M in funding of Regeneron for monoclonal antibody...
by Rod Raynovich | Nov 4, 2009 | BIOgraph
The technicals in the biotech market are looking a lot better but the damage from October was severe. The 10% correction from the Sep 21, 2009 peak is about over as long as the NASDAQ holds up. The IBB is at 75 today off its high of 84. Good news from a number of...
by Rod Raynovich | Oct 23, 2009 | BIOgraph
We commented on Tuesday about the broad selling of all biotech stocks large and small and this trend continues through today. AMGN shares are down this week despite earnings EPS of $1.49 beating estimates of $1.27 as regulatory concerns about its experimental...
by Rod Raynovich | Oct 20, 2009 | BIOgraph
Biotech stocks were in a broad retreat today for reasons that are not yet apparent as the Nasdaq and S&P were only down a modest 0.6%. Large caps that were hard hit include AMGN, BIIB,and VRTX as well as the major ETF’s IBB and XBI. My broad index of 35 mid...
by Rod Raynovich | Oct 7, 2009 | BIOgraph
Biotech summer rally sparked by deals Life Science stocks kept pace with market sectors that offer comparable risk and performance: Small cap growth, science and technology and midcap growth. The bellwether, broadly diversified ETF IBB was up 16% moving from 70 to 81...
by Rod Raynovich | Oct 2, 2009 | BIOgraph
The CDC provided a situation update regarding key flu indicators for the Week of Sep 20-26 and said that influenza activity remained elevated in virtually all states. Visits to doctors and hospitals are higher than can be expected this time of the year and almost all...
by Rod Raynovich | Aug 14, 2009 | BIOgraph
Biotech stocks followed the market down today with the NASDAQ being down 1.8% and the S&P down 1.5% . The biotech ETF’s tracked the market closely with the IBB down almost 2% and the XBI down 1.65%. The summer rally which gathered momentum with the...
by Rod Raynovich | Jul 24, 2009 | BIOgraph
Bristol Myers announced Thursday that they will buy Medarex (MEDX) for $16/share or $2.1B a 90% premium over yesterdays’ market price of $8.40. Medarex is one of the leading biotech companies focused in human antibody development for use in a broad range of...
